NextGen Healthcare vs Superluminal Medicines

Side-by-side comparison of AI visibility scores, market position, and capabilities

Superluminal Medicines leads in AI visibility (86 vs 52)
NextGen Healthcare logo

NextGen Healthcare

ChallengerHealthcare

Practice Management

Ambulatory EHR platform serving 155K providers taken private by Thoma Bravo for $1.8B; behavioral health specialty depth and AI clinical documentation modernization.

AI VisibilityBeta
Overall Score
C52
Category Rank
#3 of 4
AI Consensus
70%
Trend
stable
Per Platform
ChatGPT
53
Perplexity
46
Gemini
57

About

NextGen Healthcare is a healthcare information technology company providing electronic health record (EHR), practice management, and healthcare IT solutions primarily to ambulatory healthcare practices — physician offices, specialty clinics, and community health centers. Founded in 1974 (as Quality Systems Inc.) and headquartered in Horsham, Pennsylvania, NextGen Healthcare was taken private by Thoma Bravo in a $1.8 billion acquisition in 2023, joining a private equity firm with significant health IT portfolio investments.

Full profile
Superluminal Medicines logo

Superluminal Medicines

LeaderHealthcare

General

Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.

AI VisibilityBeta
Overall Score
A86
Category Rank
#85 of 1158
AI Consensus
59%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
80
Gemini
93

About

Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.

Full profile

AI Visibility Head-to-Head

52
Overall Score
86
#3
Category Rank
#85
70
AI Consensus
59
stable
Trend
stable
53
ChatGPT
83
46
Perplexity
80
57
Gemini
93
51
Claude
83
45
Grok
95

Key Details

Category
Practice Management
General
Tier
Challenger
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only NextGen Healthcare
Practice Management

Integrations

Only NextGen Healthcare
Only Superluminal Medicines

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.